Company: BNRG
Filing Date: 2025-11-05
Form Type: F-3/A
Source: 0001213900-25-106675
Chunk: 8

Company: Brenmiller Energy Ltd.
Filing Date: 2025-11-05
Form: F-3/A
Chunk 8
---
reement contains customary representations, warranties, covenants, and participation rights.

<div align='center'>2</div>

ABOUT THIS OFFERING This prospectus relates to the resale by the selling shareholder identified in this prospectus of up to 6,643,356 Ordinary Shares. All of the Ordinary Shares, when sold, will be sold by the selling shareholder. The selling shareholder may sell the Ordinary Shares from time to time at prevailing market prices. We will not receive any proceeds from the sale of the Ordinary Shares by the selling shareholder.

| Ordinary                                           
 Shares currently outstanding                       |     | 3,859,800                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 Ordinary Shares                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Ordinary Shares offered by the Selling Shareholder |     | Up to 6,643,356 Ordinary Shares, consisting of (i) 1,660,839 Ordinary Shares issuable upon the conversion of 3,800 Preferred Shares, with a conversion price of $2.288 per share, (ii) up to 1,660,839 Additional Preferred Shares, reflecting 200% of the maximum number of shares issuable upon conversion of the Preferred Shares (without taking into account any limitations on the conversion of such Preferred Shares set forth therein), (iii) 1,660,839 Ordinary Shares issuable upon the exercise of ordinary warrants, with an exercise price of $2.40 per share, or the Ordinary Warrants and (iv) up to 1,660,839 Additional Ordinary Warrants reflecting 200% of the maximum number of warrant shares issuable upon exercise of the Warrants (without taking into account any limitations on the exercise of such Warrants set forth therein) (see “Our Company—Recent Developments—July 2025 Private Placement” for additional information). |
| Use of proceeds:                                   |     | We will not receive any proceeds from the sale of the Ordinary Shares by the selling shareholder. All net proceeds from the sale of Ordinary Shares covered by this prospectus will go to the selling shareholder. However, we will receive cash proceeds equal to the conversion price of any Preferred Share that are converted to Ordinary Shares and the exercise price of any Warrants that are exercised. See “Use of Proceeds.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Risk factors:                                      |     | You should read the “Risk Factors” section starting on page 4 of this prospectus and “Item 3. Key Information – D. Risk Factors” in our most recent annual report on Form